Blood-based diagnostics of traumatic brain injuries

References

• Ghajar J. Traumatic brain injury. Lancet356, 923–929 (2000).
   PubMed Web of Science ®Google Scholar
• Cole TB. Global road safety crisis remedy sought, 1.2 million killed, 50 million injured annually. JAMA291, 2531–2532 (2004).
   PubMed Web of Science ®Google Scholar
• Traumatic brain injury, time to end the silence. Lancet Neurol.9, 331 (2010).
   PubMedGoogle Scholar
• Brown AF, Cullen L, Than M. Future developments in chest pain diagnosis and management. Med. Clin. North Am.94, 375–400 (2010).
   PubMed Web of Science ®Google Scholar
• Stocchetti N, Pagan F, Calappi E et al. Inaccurate early assessment of neurological severity in head injury. J. Neurotrauma21, 1131–1140 (2004).
   PubMed Web of Science ®Google Scholar
• Marion DW, Carlier PM. Problems with initial Glasgow Coma Scale assessment caused by prehospital treatment of patients with head injuries, results of a national survey. J. Trauma36, 89–95 (1994).
   PubMedGoogle Scholar
• Livingston BM, Mackenzie SJ, MacKirdy FN, Howie JC. Should the pre-sedation Glasgow Coma Scale value be used when calculating acute physiology and chronic health evaluation scores for sedated patients? Scottish Intensive Care Society Audit Group. Crit. Care Med.28, 389–394 (2000).
   PubMedGoogle Scholar
• Lindenbaum GA, Carroll SF, Daskal I, Kapusnick R. Patterns of alcohol and drug abuse in an urban trauma center, the increasing role of cocaine abuse. J. Trauma29, 1654–1658 (1989).
   PubMed Web of Science ®Google Scholar
• Corrigan JD. Substance abuse as a mediating factor in outcome from traumatic brain injury. Arch. Phys. Med. Rehab.76, 302–309 (1995).
   PubMed Web of Science ®Google Scholar
• Levi L, Guilburd JN, Lemberger A, Soustiel JF, Feinsod M. Diffuse axonal injury, analysis of 100 patients with radiological signs. Neurosurgery27(3), 429–432 (1990).
   PubMed Web of Science ®Google Scholar
• Kesler SR, Adams HF, Bigler ED. SPECT, MR and quantitative MR imaging, correlates with neuropsychological and psychological outcome in traumatic brain injury. Brain Inj.14, 851–857 (2000).
   PubMed Web of Science ®Google Scholar
• Brenner DJ, Hall EJ. Computed tomography – an increasing source of radiation exposure. N. Engl. J. Med.357, 2277–2284 (2007).
   PubMed Web of Science ®Google Scholar
• Mettler FA Jr, Bhargavan M, Faulkner K et al. Radiologic and nuclear medicine studies in the united states and worldwide, frequency, radiation dose, and comparison with other radiation sources – 1950–2007. Radiology253, 520–531 (2009).
   PubMed Web of Science ®Google Scholar
• Fazel R, Krumholz HM, Wang Y et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N. Engl. J. Med.361, 849–857 (2009).
   PubMed Web of Science ®Google Scholar
• Servadei FM, Murray GD, Penny KP et al. The value of the ‘worst’ computed tomographic scan in clinical studies of moderate and severe head injury. Neurosurgery46, 70–77 (2000).
   PubMed Web of Science ®Google Scholar
• Rimel RW, Giordani B, Barth JT, Boll TJ, Jane JA. Disability caused by minor head injury. Neurosurgery7(5), 400–408 (1981).
   Google Scholar
• Millis SR, Rosenthal MP, Novack TAP et al. Long-term neuropsychological outcome after traumatic brain injury. J. Head Trauma Rehab.16, 343–355 (2001).
   PubMed Web of Science ®Google Scholar
• Macciocchi SN, Reid DB, Barth JT. Disability following head injury. Curr. Opin. Neurol.6(5), 773–777 (1993).
   PubMed Web of Science ®Google Scholar
• Alexander MP. Mild traumatic brain injury, pathophysiology, natural history, and clinical management. Neurology45, 1253–1260 (1995).
   PubMed Web of Science ®Google Scholar
• Barth JT, Macciocchi SN, Giordani B, Rimel R, Jane JA, Boll TJ. Neuropsychological sequelae of minor head injury. Neurosurgery13, 529–533 (1983).
   PubMed Web of Science ®Google Scholar
• McCrory PR, Berkovic SF. Second impact syndrome. Neurology50, 677–683 (1998).
   PubMed Web of Science ®Google Scholar
• Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT. Classification of traumatic brain injury for targeted therapies. J. Neurotrauma25, 719–738 (2008).
   PubMed Web of Science ®Google Scholar
• Wang KK, Ottens AK, Liu MC et al. Proteomic identification of biomarkers of traumatic brain injury. Expert Rev. Proteomics2, 603–614 (2005).
   PubMed Web of Science ®Google Scholar
• Denslow N, Michel ME, Temple MD, Hsu CY, Saatman K, Hayes RL. Application of proteomics technology to the field of neurotrauma. J. Neurotrauma20, 401–407 (2003).
   PubMed Web of Science ®Google Scholar
• Burgess JA, Lescuyer P, Hainard A et al. Identification of brain cell death associated proteins in human post-mortem cerebrospinal fluid. J. Proteome Res.5, 1674–1681 (2006).
   PubMed Web of Science ®Google Scholar
• Kochanek AR, Kline AE, Gao WM et al. Gel-based hippocampal proteomic analysis 2 weeks following traumatic brain injury to immature rats using controlled cortical impact. Dev. Neurosci.28, 410–419 (2006).
   PubMedGoogle Scholar
• Yang X, Yang S, Wang J, Zhang X, Wang C, Hong G. Expressive proteomics profile changes of injured human brain cortex due to acute brain trauma. Brain Inj.23, 830–840 (2009).
   PubMed Web of Science ®Google Scholar
• Siman R, McIntosh TK, Soltesz KM, Chen Z, Neumar RW, Roberts VL. Proteins released from degenerating neurons are surrogate markers for acute brain damage. Neurobiol. Dis.16, 311–320 (2004).
   PubMed Web of Science ®Google Scholar
• Pike BR, Zhao X, Newcomb JK, Wang KK, Posmantur RM, Hayes RL. Temporal relationships between de novo protein synthesis, calpain and caspase 3-like protease activation, and DNA fragmentation during apoptosis in septo-hippocampal cultures. J. Neurosci. Res.52, 505–520 (1998).
   PubMedGoogle Scholar
• Wang KK. Calpain and caspase, can you tell the difference? Trends Neurosci.23, 20–26 (2000).
   PubMed Web of Science ®Google Scholar
• Liu J, Liu MC, Wang KK. Calpain in the CNS, from synaptic function to neurotoxicity. Sci. Signal.1(14), re1 (2008).
   PubMed Web of Science ®Google Scholar
• Liu MC, Akinyi L, Scharf D et al. Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats. Eur. J. Neurosci.31, 722–732 (2010).
   PubMed Web of Science ®Google Scholar
• Pike BR, Flint J, Dutta S, Johnson E, Wang KK, Hayes RL. Accumulation of non-erythroid α II-spectrin and calpain-cleaved α II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats. J. Neurochem.78, 1297–1306 (2001).
   PubMed Web of Science ®Google Scholar
• Ringger NC, O’Steen BE, Brabham JG et al. A novel marker for traumatic brain injury, CSF αII-spectrin breakdown product levels. J. Neurotrauma21, 1443–1456 (2004).
   PubMed Web of Science ®Google Scholar
• Pineda JA, Lewis SB, Valadka AB et al. Clinical significance of aII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J. Neurotrauma24, 354–366 (2007).
   PubMed Web of Science ®Google Scholar
• Mondello S, Robicsek S, Gabrielli A et al. αII-spectrin breakdown products (SBDPs), diagnosis and outcome in severe traumatic brain injury patients. J. Neurotrauma27, 1203–1213 (2010).
   PubMed Web of Science ®Google Scholar
• Siman R, Toraskar N, Dang A et al. A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. J. Neurotrauma26, 1867–1877 (2009).
   PubMedGoogle Scholar
• Haskins WE, Kobeissy FH, Wolper RA et al. Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE–capillary liquid chromatography–tandem mass spectrometry. J. Neurotrauma22, 629–644 (2005).
   PubMed Web of Science ®Google Scholar
• Ottens AK, Kobeissy FH, Wolper RA et al. A multidimensional differential proteomic platform using dual-phase ion-exchange chromatography–polyacrylamide gel electrophoresis/reversed-phase liquid chromatography tandem mass spectrometry. Anal. Chem.77, 4836–4845 (2005).
   PubMedGoogle Scholar
• Kobeissy FH, Ottens AK, Zhang Z et al. Novel differential neuroproteomics analysis of traumatic brain injury in rats. Mol. Cell. Proteomics5, 1887–1898 (2006).
   PubMed Web of Science ®Google Scholar
• Liu MC, Akle V, Zheng W et al. Comparing calpain- and caspase-3-mediated degradation patterns in traumatic brain injury by differential proteome analysis. Biochem. J.394, 715–725 (2006).
   PubMedGoogle Scholar
• Yao C, Williams AJ, Ottens AK et al. Detection of protein biomarkers using high-throughput immunoblotting following focal ischemic or penetrating ballistic-like brain injuries in rats. Brain Inj.22, 723–732 (2008).
   PubMed Web of Science ®Google Scholar
• Papa L, Akinyi L, Liu MC et al. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit. Care Med.38, 138–144 (2010).
   PubMed Web of Science ®Google Scholar
• Mondello S, Robicsek S, Gabrielli A et al. αII-spectrin breakdown products (SBDPs), diagnosis and outcome in severe traumatic brain injury patients. J. Neurotrauma27(7), 1203–1213 (2010).
   PubMed Web of Science ®Google Scholar
• Brophy GM, Pineda JA, Papa L et al. αII-apectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury. J. Neurotrauma26, 471–479 (2009).
   PubMed Web of Science ®Google Scholar
• Honda M, Tsuruta R, Kaneko T et al. Serum glial fibrillary acidic protein is a highly specific biomarker for traumatic brain injury in humans compared with S-100B and neuron-specific enolase. J. Trauma69(1), 104–109 (2010).
   PubMed Web of Science ®Google Scholar
• Lumpkins KM, Bochicchio GV, Keledjian K, Simard JM, McCunn M, Scalea T. Glial fibrillary acidic protein is highly correlated with brain injury. J. Trauma65, 778–782 (2008).
   PubMedGoogle Scholar
• Englebienne P. Immune and Receptor Assays in Theory and Practice. CRC Press, NJ, USA (2000).
   Google Scholar
• Sweep FC, Thomas CM, Schmitt M. analytical aspects of biomarker immunoassays in cancer research. In: Cancer Drug Discovery and Development. Gasparini G, Hayes DF (Eds). Humana Press, NJ, USA 17–30 (2010).
   Google Scholar
• Lee JW, Devanarayan V, Barrett YC et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res.23, 312–328 (2006).
   PubMed Web of Science ®Google Scholar
• Cauchon E, Liu S, Percival MD et al. Development of a homogeneous immunoassay for the detection of angiotensin I in plasma using aLISA acceptor beads technology. Anal. Biochem.388, 134–139 (2009).
   PubMed Web of Science ®Google Scholar
• Sanchez-Martinez ML, Aguilar-Caballos MP, Gomez-Hens A. Homogeneous immunoassay for soy protein determination in food samples using gold nanoparticles as labels and light scattering detection. Anal. Chim. Acta636, 58–62 (2009).
   PubMed Web of Science ®Google Scholar
• Du B, Li Z, Cheng Y. Homogeneous immunoassay based on aggregation of antibody-functionalized gold nanoparticles coupled with light scattering detection. Talanta75, 959–964 (2008).
   PubMedGoogle Scholar
• Kokko L, Kokko T, Lovgren T, Soukka T. Particulate and soluble Eu(III)-chelates as donor labels in homogeneous fluorescence resonance energy transfer based immunoassay. Anal. Chim. Acta606, 72–79 (2008).
   PubMedGoogle Scholar
• Kuningas K, Rantanen T, Ukonaho T, Lovgren T, Soukka T. Homogeneous assay technology based on upconverting phosphors. Anal. Chem.77, 7348–7355 (2005).
   PubMedGoogle Scholar
• Vaisocherova H, Faca VM, Taylor AD, Hanash S, Jiang S. Comparative study of SPR and ELISA methods based on analysis of CD166/ALCAM levels in cancer and control human sera. Biosens. Bioelectron.24, 2143–2148 (2009).
   PubMedGoogle Scholar
• Bothara M, Venkatraman V, Reddy RK, Barrett T, Carruthers J, Prasad S. Nanomonitors, electrical immunoassays for protein biomarker profiling. Nanomed. (Lond.)3, 423–436 (2008).
   PubMedGoogle Scholar
• Wasowicz M, Viswanathan S, Dvornyk A, Grzelak K, Kludkiewicz B, Radecka H. Comparison of electrochemical immunosensors based on gold nano materials and immunoblot techniques for detection of histidine-tagged proteins in culture medium. Biosens. Bioelectron.24, 284–289 (2008).
   PubMed Web of Science ®Google Scholar
• Indyk HE, Filonzi EL. Direct optical biosensor analysis of folate-binding protein in milk. J. Agric. Food Chem.52, 3253–3258 (2004).
   PubMed Web of Science ®Google Scholar
• Davis F, Higson SP. Label-free immunochemistry approach to detect and identity antibiotics in milk. Pediatr. Res.67, 476–480 (2010).
   PubMedGoogle Scholar
• Sun AL, Qi QA, Dong ZL. Label-free electrochemical immunosensor for the determination of fetoprotein based on core-shell–shell nanocomposite particles. Protein Pept. Lett.15, 782–788 (2008).
   PubMedGoogle Scholar
• Lai NS, Wang CC, Chiang HL, Chau LK. Detection of antinuclear antibodies by a colloidal gold modified optical fiber, comparison with ELISA. Anal. Bioanal. Chem.388, 901–907 (2007).
   PubMed Web of Science ®Google Scholar
• Swanson SJ, Jacobs SJ, Mytych D, Shah C, Indelicato SR, Bordens RW. Applications for the new electrochemiluminescent (ECL) and biosensor technologies. Dev. Biol. Stand.97, 135–147 (1999).
   PubMedGoogle Scholar
• Malmqvist M. Epitope mapping by label-free biomolecular interaction analysis. Methods9, 525–532 (1996).
   PubMedGoogle Scholar
• Wu M, Long S, Frutos AG, Eichelberger M, Li M, Fang Y. Interrogation of phosphor-specific interaction on a high-throughput label-free optical biosensor system – epic system. J. Recept. Signal. Transduct. Res.29, 202–210 (2009).
   PubMed Web of Science ®Google Scholar
• Fang Y, Frutos AG, Verklereen R. Label-free cell-based assays for GPCR screening. Comb. Chem. High Throughput Screen.11, 357–369 (2008).
   PubMed Web of Science ®Google Scholar
• Tang L, Dong C, Ren J. Highly sensitive homogenous immunoassay of cancer biomarker using silver nanoparticles enhanced fluorescence correlation spectroscopy. Talanta81, 1560–1567 (2010).
   PubMed Web of Science ®Google Scholar
• Franek M, Zeravik J, Eremin SA et al. Antibody-based methods for surfactant screening. Fresenius J. Anal. Chem.371, 456–466 (2001).
   PubMedGoogle Scholar
• Muller UR. Protein detection using biobarcodes. Mol. Biosyst.2, 470–476 (2006).
   PubMedGoogle Scholar
• Ingebrigtsen T, Romner B. Biochemical serum markers of traumatic brain injury. J. Trauma52, 798–808 (2002).
   PubMedGoogle Scholar
• Kochanek PM, Berger RP, Bayir H, Wagner AK, Jenkins LW, Clark RS. Biomarkers of primary and evolving damage in traumatic and ischemic brain injury, diagnosis, prognosis, probing mechanisms, and therapeutic decision making. Curr. Opin. Crit. Care14, 135–141 (2008).
   PubMed Web of Science ®Google Scholar
• Lyeth BG, Jiang JY, Robinson SE, Guo H, Jenkins LW. Hypothermia blunts acetylcholine increase in CSF of traumatically brain injured rats. Mol. Chem. Neuropathol.18, 247–256 (1993).
   PubMedGoogle Scholar
• Papa L, Robinson G, Oli MW et al. Use of biomarkers for diagnosis and management of traumatic brain injury patients. Expert Opin. Med. Diagn.2, 937–945 (2008).
   PubMedGoogle Scholar
• Raabe A, Grolms C, Seifert V. Serum markers of brain damage and outcome prediction in patients after severe head injury. Br. J. Neurosurg.13, 56–59 (1999).
   PubMed Web of Science ®Google Scholar
• Robinson SE, Martin RM, Davis TR, Gyenes CA, Ryland JE, Enters EK. The effect of acetylcholine depletion on behavior following traumatic brain injury. Brain Res.509, 41–46 (1990).
   PubMedGoogle Scholar
• Raabe A, Seifert V. Fatal secondary increase in serum S-100B protein after severe head injury. Report of three cases. J. Neurosurg.91, 875–877 (1999).
   PubMed Web of Science ®Google Scholar
• Zemlan FP, Rosenberg WS, Luebbe PA et al. Quantification of axonal damage in traumatic brain injury, affinity purification and characterization of cerebrospinal fluid tau proteins. J. Neurochem.72, 741–750 (1999).
   PubMed Web of Science ®Google Scholar
• Clark RS, Kochanek PM, Adelson PD et al. Increases in bcl-2 protein in cerebrospinal fluid and evidence for programmed cell death in infants and children after severe traumatic brain injury. J. Pediatr.137, 197–204 (2000).
   PubMed Web of Science ®Google Scholar
• Tapiola T, Pirttila T, Mikkonen M et al. Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer’s disease. Neurosci. Lett.280, 119–122 (2000).
   PubMed Web of Science ®Google Scholar
• Haber B, Grossman RG. Acetylcholine metabolism in intracranial and lumbar cerebrospinal fluid and in blood. In: Neurobiology of Cerebrospinal Fluid. Wood JH (Ed.). Plentum Press, NY, USA 345–350 (1980).
   Google Scholar
• Xiong H, Liang WL, Wu XR. [Pathophysiological alterations in cultured astrocytes exposed to hypoxia/reoxygenation]. Sheng Li Ke Xue Jin Zhan31, 217–221 (2000).
   PubMedGoogle Scholar
• Raabe A, Grolms C, Keller M, Dohnert J, Sorge O, Seifert V. Correlation of computed tomography findings and serum brain damage markers following severe head injury. Acta Neurochir. (Wien)140, 787–791 (1998).
   PubMed Web of Science ®Google Scholar
• Romner B, Ingebrigtsen T, Kongstad P, Borgesen SE. Traumatic brain damage, serum S-100 protein measurements related to neuroradiological findings. J. Neurotrauma17, 641–647 (2000).
   PubMed Web of Science ®Google Scholar
• Woertgen C, Rothoerl RD, Metz C, Brawanski A. Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury. J. Trauma47, 1126–1130 (1999).
   PubMed Web of Science ®Google Scholar
• Raabe A, Grolms C, Sorge O, Zimmermann M, Seifert V. Serum S-100B protein in severe head injury. Neurosurgery45, 477–483 (1999).
   PubMed Web of Science ®Google Scholar
• Rothoerl RD, Woertgen C, Holzschuh M, Metz C, Brawanski A. S-100 serum levels after minor and major head injury. J. Trauma45, 765–767 (1998).
   PubMed Web of Science ®Google Scholar
• Herrmann M, Curio N, Jost S, Wunderlich MT, Synowitz H, Wallesch CW. Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury. Restor. Neurol. Neurosci.14, 109–114 (1999).
   Web of Science ®Google Scholar
• McKeating EG, Andrews PJ, Mascia L. Relationship of neuron specific enolase and protein S-100 concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury. Acta Neurochir. Suppl.71, 117–119 (1998).
   PubMedGoogle Scholar
• Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H. GFAP versus S100B in serum after traumatic brain injury, relationship to brain damage and outcome. J. Neurotrauma21, 1553–1561 (2004).
   PubMed Web of Science ®Google Scholar
• Woertgen C, Rothoerl RD, Holzschuh M, Metz C, Brawanski A. Comparison of serial S-100 and NSE serum measurements after severe head injury. Acta Neurochir. (Wien)139, 1161–1164 (1997).
   PubMed Web of Science ®Google Scholar
• Rothoerl RD, Woertgen C. High serum S100B levels for trauma patients without head injuries. Neurosurgery49, 1490–1491 (2001).
   PubMedGoogle Scholar
• Anderson RE, Hansson LO, Nilsson O, Dijlai-Merzoug R, Settergren G. High serum S100B levels for trauma patients without head injuries. Neurosurgery48, 1255–1258 (2001).
   PubMed Web of Science ®Google Scholar
• Romner B, Ingebrigtsen T. High serum S100B levels for trauma patients without head injuries. Neurosurgery49, 1490–1493 (2001).
   PubMedGoogle Scholar
• Jonsson H, Johnsson P, Backstrom M, Alling C, Dautovic-Bergh C, Blomquist S. Controversial significance of early S100B levels after cardiac surgery. BMC Neurol.4, 24 (2004).
   PubMedGoogle Scholar
• Routsi C, Stamataki E, Nanas S et al. Increased levels of serum S100B protein in critically ill patients without brain injury. Shock26, 20–24 (2006).
   PubMed Web of Science ®Google Scholar
• Berger RP, Dulani T, Adelson PD, Leventhal JM, Richichi R, Kochanek PM. Identification of inflicted traumatic brain injury in well-appearing infants using serum and cerebrospinal markers, a possible screening tool. Pediatrics117, 325–332 (2006).
   PubMed Web of Science ®Google Scholar
• Piazza O, Storti MP, Cotena S et al. S100B is not a reliable prognostic index in paediatric TBI. Pediatr. Neurosurg.43, 258–264 (2007).
   PubMed Web of Science ®Google Scholar
• Gonçalves CA, Leite MC, Nardin P. Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin. Biochem.41, 755–763 (2008).
   PubMed Web of Science ®Google Scholar
• Bloomfield SM, McKinney J, Smith L et al. Reliability of S100B in predicting severity of central nervous system injury. Neurocrit. Care6, 121–138 (2007).
   PubMed Web of Science ®Google Scholar
• Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu. Rev. Neurosci.10, 269–295 (1987).
   PubMed Web of Science ®Google Scholar
• Vos PE, Lamers KJ, Hendriks JC et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology62, 1303–1310 (2004).
   PubMed Web of Science ®Google Scholar
• Ross SA, Cunningham RT, Johnston CF, Rowlands BJ. Neuron-specific enolase as an aid to outcome prediction in head injury. Br. J. Neurosurg.10, 471–476 (1996).
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Yada K, Morii S, Kitahara T, Ohwada T. Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. Surg. Neurol.43, 267–270 (1995).
   PubMed Web of Science ®Google Scholar
• Jonsson H, Johnsson P, Backstrom M, Alling C, Dautovic-Bergh C, Blomquist S. Controversial significance of early S100B levels after cardiac surgery. BMC Neurol.4, 24 (2004).
   PubMedGoogle Scholar
• Pelinka LE, Hertz H, Mauritz W et al. Nonspecific increase of systemic neuron-specific enolase after trauma, clinical and experimental findings. Shock24, 119–123 (2005).
   PubMedGoogle Scholar
• Palfreyman JW, Thomas DG, Ratcliffe JG. Radioimmunoassay of human myelin basic protein in tissue extract, cerebrospinal fluid and serum and its clinical application to patients with head injury. Clin. Chim. Acta82, 259–270 (1978).
   PubMedGoogle Scholar
• Thomas DG, Palfreyman JW, Ratcliffe JG. Serum-myelin-basic-protein assay in diagnosis and prognosis of patients with head injury. Lancet1, 113–115 (1978).
   PubMed Web of Science ®Google Scholar
• Thomas DG, Rabow L, Teasdale G. Serum myelin basic protein, clinical responsiveness, and outcome of severe head injury. Acta Neurochir. Suppl. (Wien)28, 93–95 (1979).
   PubMedGoogle Scholar
• Berger RP, Adelson PD, Pierce MC, Dulani T, Cassidy LD, Kochanek PM. Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J. Neurosurg.103, 61–68 (2005).
   PubMed Web of Science ®Google Scholar
• Tongaonkar P, Chen L, Lambertson D, Ko B, Madura K. Evidence for an interaction between ubiquitin-conjugating enzymes and the 26S proteasome. Mol. Cell. Biol.20, 4691–4698 (2000).
   PubMed Web of Science ®Google Scholar
• Gong B, Leznik E. The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect.20, 365–370 (2007).
   PubMed Web of Science ®Google Scholar
• Papa L, Akinyi L, Liu MC et al. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit. Care Med.38, 138–144 (2010).
   PubMed Web of Science ®Google Scholar
• Eng LF, Vanderhaeghen JJ, Bignami A, Gerstl B. An acidic protein isolated from fibrous astrocytes. Brain Res.28, 351–354 (1971).
   PubMed Web of Science ®Google Scholar
• Eng LF. Proteins of the Nervous System. Raven Press, NY, USA 85–117 (2010).
   Google Scholar
• Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem. Res.25, 1439–1451 (2000).
   PubMed Web of Science ®Google Scholar
• Missler U, Wiesmann M, Wittmann G, Magerkurth O, Hagenstrom H. Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin. Chem.45, 138–141 (1999).
   PubMed Web of Science ®Google Scholar
• Pelinka LE, Kroepfl A, Schmidhammer R et al. Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J. Trauma57, 1006–1012 (2004).
   PubMed Web of Science ®Google Scholar
• Van Geel WJ, De Reus HP, Nijzing H, Verbeek MM, Vos PE, Lamers KJ. Measurement of glial fibrillary acidic protein in blood, an analytical method. Clin. Chim. Acta326, 151–154 (2002).
   PubMed Web of Science ®Google Scholar
• Pike BR, Flint J, Dave JR et al. Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived aII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. J. Cereb. Blood Flow Metab.24, 98–106 (2004).
   PubMed Web of Science ®Google Scholar
• Riederer BM, Zagon IS, Goodman SR. Brain spectrin (240/235) and brain spectrin (240/235E): two distinct spectrin subtypes with different locations within mammalian neural cells. J. Cell Biol.102, 2088–2097 (1986).
   PubMed Web of Science ®Google Scholar
• Wang KK, Posmantur R, Nath R et al. Simultaneous degradation of aII- and bII-spectrin by caspase 3 (CPP32) in apoptotic cells. J. Biol. Chem.273, 22490–22497 (1998).
   PubMed Web of Science ®Google Scholar
• Narayan RK, Michel ME, Ansell B et al. Clinical trials in head injury. J. Neurotrauma19, 503–557 (2002).
   PubMed Web of Science ®Google Scholar
• Chesnut RM, Marshall LF, Klauber MR et al. The role of secondary brain injury in determining outcome from severe head injury. J. Trauma34, 216–222 (1993).
   PubMed Web of Science ®Google Scholar
• Alberico AM, Ward JD, Choi SC, Marmarou A, Young HF. Outcome after severe head injury. Relationship to mass lesions, diffuse injury, and ICP course in pediatric and adult patients. J. Neurosurg.67, 648–656 (1987).
   PubMed Web of Science ®Google Scholar
• Marmarou A. Neurotrauma. McGraw-Hill, NY, USA (1996).
   Google Scholar
• Hemphill JC III, Barton CW, Morabito D, Manley GT. Influence of data resolution and interpolation method on assessment of secondary brain insults in neurocritical care. Physiol. Meas.26, 373–386 (2005).
   PubMedGoogle Scholar
• Langlois JA, Rutland-Brown W, Thomas KE. Traumatic Brain Injury in the United States, Emergency Department Visits, Hospitalizations, and Deaths. US Department of Health and Human Services, CDC, GA, USA (2004).
   Google Scholar
• Clifton GL, Miller ER, Choi SC et al. Lack of effect of induction of hypothermia after acute brain injury. N. Engl. J. Med.344, 556–563 (2001).
   PubMed Web of Science ®Google Scholar
• McHugh GS, Engel DC, Butcher I et al. Prognostic value of secondary insults in traumatic brain injury: results from the IMPACT study. J. Neurotrauma24, 287–293 (2007).
   PubMed Web of Science ®Google Scholar